<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04925193</url>
  </required_header>
  <id_info>
    <org_study_id>20-2202.cc</org_study_id>
    <secondary_id>P30CA046934</secondary_id>
    <nct_id>NCT04925193</nct_id>
  </id_info>
  <brief_title>Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma</brief_title>
  <official_title>Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Karyopharm Therapeutics Inc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Selinexor (KPT-330, Xpovio) is a first in class selective inhibitor of nuclear export which&#xD;
      has been approved for use in relapsed and refractory multiple myeloma (RRMM). This trial will&#xD;
      seek to evaluate the outcomes achieved with selinexor based combination in RRMM selected by&#xD;
      physician's choice and compared prospectively to ex vivo drug sensitivity testing results.&#xD;
      Participants will be enrolled and assigned into one of the following treatment arms:&#xD;
&#xD;
      Arm 1: Selinexor + pomalidomide + dexamethasone (SPd)&#xD;
&#xD;
      Arm 2: Selinexor + daratumumab + dexamethasone (SDd)&#xD;
&#xD;
      Arm 3: Selinexor + carfilzomib + dexamethasone (SKd)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a single institution, open-label phase II study to evaluate the overall&#xD;
      response rate achieved with selinexor and dexamethasone based three drug combination therapy,&#xD;
      selected by physician's choice, in patients with relapsed/refractory multiple myeloma.&#xD;
&#xD;
      Patients with RRMM will be eligible for enrollment. During screening, in addition to standard&#xD;
      of care disease assessments, participant's bone marrow aspirate will be evaluated using a&#xD;
      novel ex vivo Myeloma Drug Sensitivity Testing platform (My-DST). The following agents will&#xD;
      be eligible for physician's choice, and in parallel evaluated for sample sensitivity in&#xD;
      MyDST: pomalidomide, carfilzomib and daratumumab. Agents will be tested individually, in&#xD;
      combination with selinexor and in combination with selinexor and dexamethasone. Results from&#xD;
      MyDST will be not be available to investigators at time of treatment assignment, but will be&#xD;
      evaluated to better characterize test performance and relationship with treatment outcomes.&#xD;
&#xD;
      Investigators will assign patients to one of the following treatment combinations:&#xD;
      Selinexor/Pomalidomide/Dexamethsone (SPd), Selinexor/Daratumumab/Dexamethasone (SDd) or&#xD;
      Selinexor/Carfilzomib/Dexamethasone (SKd). Investigators will use patient specific&#xD;
      considerations such as prior therapeutic exposures, response to / tolerance of prior&#xD;
      therapies and comorbid conditions which may increase risk for toxicity with specific agents&#xD;
      to guide expert judgement in selecting partner agent for selinexor and dexamethasone.&#xD;
      Treatment will continue until progression of disease, unacceptable toxicity or death.&#xD;
&#xD;
      This study will evaluate if physician's choice partner drug selection for selinexor based&#xD;
      combination therapy in RRMM will lead to an overall response rate of 75% or higher.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2021</start_date>
  <completion_date type="Anticipated">November 2025</completion_date>
  <primary_completion_date type="Anticipated">November 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response rate</measure>
    <time_frame>Two years</time_frame>
    <description>To evaluate the overall response rate achieved with physician's choice selinexor-based combination therapy as measured by International Myeloma Working Group criteria (based on Kumar et al 2016)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>MRD negative response rate</measure>
    <time_frame>2 years</time_frame>
    <description>To evaluate the minimal residual disease negative response rate achieved with physician's choice selinexor-based combination therapy assessed via NGS or multiparametric flow cytometry with sensitivity of 10-5.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>2 years</time_frame>
    <description>To evaluate the duration of progression free survival achieved with physician's choice selinexor-based combination therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>2 years</time_frame>
    <description>To evaluate the duration of overall survival achieved with physician's choice selinexor-based combination therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>2 years</time_frame>
    <description>To evaluate the duration of response achieved with physician's choice selinexor-based combination therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Next Treatment</measure>
    <time_frame>2 years</time_frame>
    <description>To evaluate the time to next treatment achieved with physician's choice selinexor-based combination therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of selinexor</measure>
    <time_frame>2 years</time_frame>
    <description>To evaluate safety and tolerability of selinexor in combination with partner backbone agents using occurrence, nature and severity of Adverse Events</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Reliability of My-DST testing to inform treatment choice</measure>
    <time_frame>2 years</time_frame>
    <description>Rate of assay failure</description>
  </other_outcome>
  <other_outcome>
    <measure>Feasibility of My-DST testing to inform treatment choice</measure>
    <time_frame>2 years</time_frame>
    <description>Rate of identification of preferred partner therapy or combination</description>
  </other_outcome>
  <other_outcome>
    <measure>Evaluation of My-DST related predictors of response</measure>
    <time_frame>2 years</time_frame>
    <description>ORR in patients with concordance or discordance between My-DST results and physicians selected regimen</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Multiple Myeloma in Relapse</condition>
  <arm_group>
    <arm_group_label>Arm 1 SPd</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Selinexor 60 mg PO days 1, 8, 15&#xD;
Pomalidomide 4 mg PO on days 1-21&#xD;
Dexamethasone 40 mg PO or IV on days 1, 8, 15, 22&#xD;
28 day treatment cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2 SDd</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Selinexor 80 mg PO days 1, 8, 15&#xD;
Daratumumab 1,800mg/30,000 units subcutaneous injection on days 1, 8, 15, 22 of cycles 1 and 2, days 1, 15 of cycles 3-6, day 1 of cycles &gt;6&#xD;
Dexamethasone 40 mg PO or IV days 1, 8, 15, 22&#xD;
28 day treatment cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3 SKd</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Selinexor 80 mg PO days 1, 8, 15&#xD;
Carfilzomib IV infusion 20 mg/m2 cycle 1, day 1, 56 mg/m2 cycle 1 day 8, 15. Cycle 2+ days 1, 8, 15.&#xD;
Dexamethasone 40 mg IV or PO days 1, 8, 15, 22&#xD;
28 day treatment cycle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Selinexor</intervention_name>
    <description>Selinexor is an oral, first-in-class, slowly reversible, potent selective inhibitor of nuclear export (SINE) compound that specifically blocks exportin 1 (XPO1).</description>
    <arm_group_label>Arm 1 SPd</arm_group_label>
    <arm_group_label>Arm 2 SDd</arm_group_label>
    <arm_group_label>Arm 3 SKd</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pomalidomide</intervention_name>
    <description>Oral Table</description>
    <arm_group_label>Arm 1 SPd</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daratumumab</intervention_name>
    <description>Injection</description>
    <arm_group_label>Arm 2 SDd</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carfilzomib</intervention_name>
    <description>Injection</description>
    <arm_group_label>Arm 3 SKd</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Oral tablet or injection</description>
    <arm_group_label>Arm 1 SPd</arm_group_label>
    <arm_group_label>Arm 2 SDd</arm_group_label>
    <arm_group_label>Arm 3 SKd</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥ 18 years&#xD;
&#xD;
          2. Willing and able to provide written informed consent in accordance with federal,&#xD;
             local, and institutional guidelines. The patient must provide informed consent prior&#xD;
             to the first screening procedure.&#xD;
&#xD;
          3. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of ≤ 2&#xD;
&#xD;
          4. Histologically confirmed diagnosis, measurable disease and evidence of disease&#xD;
             progression of MM after 1 or more prior lines of therapy with either of the following:&#xD;
&#xD;
               1. Documented evidence of PD after achieving at least SD for ≥ 1 cycle during a&#xD;
                  previous MM regimen (i.e., relapsed MM)&#xD;
&#xD;
               2. ≤ 25% response (i.e, patient never achieved ≥ MR) or PD during or within 60 days&#xD;
                  from end of the most recent MM regimen (i.e., refractory MM)&#xD;
&#xD;
          5. Patients must have measurable disease as defined by at least one of the following:&#xD;
&#xD;
               1. Serum M-protein ≥ 0.5 g/dL by serum protein electrophoresis (SPEP) or, for IgA&#xD;
                  myeloma, by quantitative IgA&#xD;
&#xD;
               2. Urinary M-protein excretion at least 200 mg/24 hours&#xD;
&#xD;
               3. Serum FLC ≥ 10 mg/dL, provided that FLC ratio is abnormal&#xD;
&#xD;
               4. If no measurable disease by serum or urine, then the presence of a plasmacytoma&#xD;
                  of ≥2cm in one dimension prior to start of study can be used to follow response&#xD;
                  via radiologic imaging.&#xD;
&#xD;
          6. Adequate hepatic function:&#xD;
&#xD;
               1. Total bilirubin &lt; 1.5 × upper limit of normal (ULN) (except patients with&#xD;
                  Gilbert's syndrome who must have a total bilirubin of &lt; 3 × ULN), and&#xD;
&#xD;
               2. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) normal to&#xD;
                  &lt;2.5 × ULN.&#xD;
&#xD;
          7. Adequate renal function as determined by serum creatinine of ≤2 mg/dL OR estimated&#xD;
             creatinine clearance of ≥ 20 mL/min, calculated using the Cockcroft and Gault formula&#xD;
             (140 - Age) • Mass (kg)/ (72 • creatinine mg/dL); multiply by 0.85 if female&#xD;
             (Cockcroft 1976).&#xD;
&#xD;
          8. Adequate hematopoietic function within 7 days prior to C1D1: absolute neutrophil count&#xD;
             ≥1000/mm3, hemoglobin ≥8 g/dL and platelet count ≥100,000/mm3 (patients for whom &lt;50%&#xD;
             of bone marrow nucleated cells are plasma cells) or ≥50,000/mm3 (patients for whom&#xD;
             ≥50% of bone marrow nucleated cells are plasma cells).&#xD;
&#xD;
               1. Patients may receive hematopoietic growth factor support, including&#xD;
                  erythropoietin, darbepoetin, granulocyte-colony stimulating factor (G-CSF),&#xD;
                  granulocyte macrophage-colony stimulating factor (GM-CSF), and platelet&#xD;
                  stimulators (eg, eltrombopag, romiplostim, or interleukin-11) at any time.&#xD;
&#xD;
               2. Patients may receive RBC and/or platelet transfusions as clinically indicated per&#xD;
                  institutional guidelines during the study.&#xD;
&#xD;
          9. Female patients of childbearing potential must have a negative serum pregnancy test at&#xD;
             Screening. Female patients of childbearing potential and fertile male patients who are&#xD;
             sexually active with a female of childbearing potential must use highly effective&#xD;
             methods of contraception throughout the study and for 3 months following the last dose&#xD;
             of study treatment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Has received selinexor or another SINE (Specific Inhibitor of Nuclear Export) compound&#xD;
             in a previous line of therapy.&#xD;
&#xD;
          2. Has any concurrent medical condition or disease (eg, uncontrolled active hypertension,&#xD;
             uncontrolled active diabetes, active systemic infection, etc.) that is likely to&#xD;
             interfere with study procedures.&#xD;
&#xD;
          3. Uncontrolled active infection requiring parenteral antibiotics, antivirals, or&#xD;
             antifungals within 1 week prior to Cycle 1 Day 1 (C1D1). Patients on prophylactic&#xD;
             antibiotics or with a controlled infection within 1 week prior to C1D1 are acceptable.&#xD;
&#xD;
          4. Known intolerance, hypersensitivity, or contraindication to study drugs.&#xD;
&#xD;
          5. Pregnant or breastfeeding females.&#xD;
&#xD;
          6. Major surgery within 4 weeks prior to C1D1.&#xD;
&#xD;
          7. Active, unstable cardiovascular function, as indicated by the presence of:&#xD;
&#xD;
               1. Symptomatic ischemia, or&#xD;
&#xD;
               2. Uncontrolled clinically significant conduction abnormalities (eg, patients with&#xD;
                  ventricular tachycardia on anti-arrhythmics are excluded; patients with first&#xD;
                  degree atrioventricular block or asymptomatic left anterior fascicular&#xD;
                  block/right bundle branch block will not be excluded), or&#xD;
&#xD;
               3. Congestive heart failure of New York Heart Association Class ≥3 or known left&#xD;
                  ventricular ejection fraction &lt;40%, or&#xD;
&#xD;
               4. Myocardial infarction within 3 months prior to C1D1.&#xD;
&#xD;
          8. Subjects with active hepatitis B virus (Hep B) are allowed if antiviral therapy for&#xD;
             hepatitis B has been given for &gt;8 weeks and viral load is &lt;100 IU/ml prior to first&#xD;
             dose of trial treatment. Subjects with untreated hepatitis C virus (HCV) are allowed.&#xD;
             Subjects with Human Immunodeficiency Virus (HIV) who have CD4+ T-cell counts ≥ 350&#xD;
             cells/µL and no history of AIDS-defining opportunistic infections in the last year are&#xD;
             allowed.&#xD;
&#xD;
          9. Any active gastrointestinal dysfunction interfering with the patient's ability to&#xD;
             swallow tablets, or any active gastrointestinal dysfunction that could interfere with&#xD;
             absorption of study treatment, including prior gastric bypass or bowel resection&#xD;
             procedures.&#xD;
&#xD;
         10. Inability or unwillingness to take supportive medications such as anti-nausea and&#xD;
             anti-anorexia agents as recommended by the National Comprehensive Cancer Network®&#xD;
             (NCCN) Clinical Practice Guidelines in Oncology (CPGO) (NCCN CPGO) for antiemesis and&#xD;
             anorexia/cachexia (palliative care).&#xD;
&#xD;
         11. Any active, serious psychiatric, medical, or other conditions/situations that, in the&#xD;
             opinion of the Investigator, could interfere with treatment, compliance, or the&#xD;
             ability to give informed consent.&#xD;
&#xD;
         12. Contraindication to any of the required concomitant drugs or supportive treatments.&#xD;
&#xD;
         13. Patients unwilling or unable to comply with the protocol, including providing 24-hour&#xD;
             urine samples for urine protein electrophoresis at the required time points.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Derek Schatz</last_name>
    <phone>720-848-0628</phone>
    <email>derek.schatz@cuanschutz.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Colorado Hospital</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Derek Schatz</last_name>
      <phone>720-848-0628</phone>
      <email>derek.schatz@cuanschutz.edu</email>
    </contact>
    <investigator>
      <last_name>Peter Forsberg</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>May 19, 2021</study_first_submitted>
  <study_first_submitted_qc>June 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 14, 2021</study_first_posted>
  <last_update_submitted>October 25, 2021</last_update_submitted>
  <last_update_submitted_qc>October 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Pomalidomide</mesh_term>
    <mesh_term>Daratumumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

